Whitehawk Therapeutics (WHWK) Current Assets (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 15 years of Current Assets data on file, last reported at $125.5 million in Q1 2026.

• Current Assets for Q1 2026 came in at $125.5 million, down 46.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $125.5 million (down 46.03% YoY), and the FY2025 annual result was $149.0 million, up 143.14% from the prior year.
• Current Assets retreated to $125.5 million in Q1 2026 per WHWK's latest filing, from $149.0 million in the prior quarter.
• Over five years, Current Assets peaked at $232.6 million in Q1 2025 and troughed at $61.3 million in Q4 2024.
• A 5-year average of $140.1 million and a median of $135.6 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2022 and 2024: Current Assets soared 232.49% in 2022, then sank 50.81% in 2024.
• A 5-year view of Current Assets shows it stood at $180.0 million in 2022, then plunged by 30.8% to $124.6 million in 2023, then plunged by 50.81% to $61.3 million in 2024, then soared by 143.14% to $149.0 million in 2025, then retreated by 15.75% to $125.5 million in 2026.
• Business Quant data shows WHWK's Current Assets at $125.5 million in Q1 2026, $149.0 million in Q4 2025, and $165.0 million in Q3 2025.